JP2009533482A5 - - Google Patents

Download PDF

Info

Publication number
JP2009533482A5
JP2009533482A5 JP2009506726A JP2009506726A JP2009533482A5 JP 2009533482 A5 JP2009533482 A5 JP 2009533482A5 JP 2009506726 A JP2009506726 A JP 2009506726A JP 2009506726 A JP2009506726 A JP 2009506726A JP 2009533482 A5 JP2009533482 A5 JP 2009533482A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
anticancer agent
opioid antagonist
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009506726A
Other languages
English (en)
Japanese (ja)
Other versions
JP5451378B2 (ja
JP2009533482A (ja
Filing date
Publication date
Priority claimed from US11/379,010 external-priority patent/US8524731B2/en
Application filed filed Critical
Publication of JP2009533482A publication Critical patent/JP2009533482A/ja
Publication of JP2009533482A5 publication Critical patent/JP2009533482A5/ja
Application granted granted Critical
Publication of JP5451378B2 publication Critical patent/JP5451378B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009506726A 2006-04-17 2007-04-17 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用 Active JP5451378B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/379,010 US8524731B2 (en) 2005-03-07 2006-04-17 Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US11/379,010 2006-04-17
PCT/US2007/066806 WO2007121447A2 (en) 2006-04-17 2007-04-17 Use of opioid antagonists to attenuate endothelial cell proliferation and migration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013269363A Division JP2014097993A (ja) 2006-04-17 2013-12-26 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用

Publications (3)

Publication Number Publication Date
JP2009533482A JP2009533482A (ja) 2009-09-17
JP2009533482A5 true JP2009533482A5 (enExample) 2010-09-24
JP5451378B2 JP5451378B2 (ja) 2014-03-26

Family

ID=38610448

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009506726A Active JP5451378B2 (ja) 2006-04-17 2007-04-17 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用
JP2013269363A Withdrawn JP2014097993A (ja) 2006-04-17 2013-12-26 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013269363A Withdrawn JP2014097993A (ja) 2006-04-17 2013-12-26 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用

Country Status (6)

Country Link
US (2) US8524731B2 (enExample)
EP (1) EP2010176A2 (enExample)
JP (2) JP5451378B2 (enExample)
AU (1) AU2007237943B2 (enExample)
CA (2) CA2649710C (enExample)
WO (1) WO2007121447A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0409133B8 (pt) 2003-04-08 2021-05-25 Progenics Pharm Inc preparações farmacêuticas estavéis compreendendo metilnaltrexona
BRPI0608818A2 (pt) 2005-03-07 2010-01-26 Univ Chicago uso de antagonista opióides para atenuação de proliferação e migração de células endoteliais
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US7914776B2 (en) * 2005-10-07 2011-03-29 Adolor Corporation Solid dispersions of opioid antagonists
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
EP2134718A2 (en) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
CA2682125C (en) 2007-03-29 2015-06-16 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
WO2008151019A1 (en) * 2007-05-30 2008-12-11 University Of Florida Research Foundation, Inc. Extended release of bioactive molecules from silicone hydrogels
CA2713568C (en) 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
AU2009225434B2 (en) * 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
EP2306829B1 (en) 2008-07-01 2017-01-04 University of Chicago Particles containing a peripheral opioid receptor antagonist
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
CN102325776A (zh) * 2009-02-23 2012-01-18 马林克罗特公司 (+)-吗啡喃*季盐及其制备方法
WO2010096791A1 (en) * 2009-02-23 2010-08-26 Mallinckrodt Inc. (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
JP5797655B2 (ja) * 2009-09-18 2015-10-21 アドラー・コーポレーション 消化管障害のためのオピオイド受容体アンタゴニストの使用
KR20110053639A (ko) * 2009-11-16 2011-05-24 강원대학교산학협력단 모르피난 알칼로이드계 화합물을 유효성분으로 함유하는 항암 또는 면역 증강용 조성물
BR112013024137A2 (pt) * 2011-03-31 2017-09-26 Imuneks Farma Ilac Sanayi Ve Ticaret A S composições de antagonistas de opióides e seu uso para o tratamento da esclerodermia
JP2015107918A (ja) * 2012-02-14 2015-06-11 国立研究開発法人国立がん研究センター 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法
KR102196450B1 (ko) * 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
JP5892198B2 (ja) * 2014-06-26 2016-03-23 横浜ゴム株式会社 モールドの洗浄システム
WO2016061531A1 (en) * 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
EP3847247A4 (en) * 2018-09-06 2022-12-21 University of South Alabama Infection-induced endothelial amyloid compositions as antimicrobials
WO2021178541A1 (en) * 2020-03-06 2021-09-10 Sintetica S.A. Drug combinations for inhibiting inflammation and src kinase activation following invasive surgical procedures
TW202400158A (zh) * 2022-03-10 2024-01-01 美商葛萊希克斯莫爾公司 以μ-阿片受體拮抗劑治療癌症及其他病症的方法

Family Cites Families (237)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2459955A (en) * 1945-10-17 1949-01-25 Shawinigan Chem Ltd Polyvinyl acetate emulsion adhesive
DE1420015B1 (de) * 1959-10-16 1971-08-26 Boehringer Sohn Ingelheim 2'-Hydroxy-5,9-dimethyl-6,7-benzomorphane
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3725311A (en) * 1972-05-15 1973-04-03 Thuron Industries Low temperature extrudable odor-neutralizing composition
US3937801A (en) * 1973-07-10 1976-02-10 American Home Products Corporation Reducing the incidence of gastrointestinal side effects during the treatment of inflammatory conditions with antiinflammatory drugs
US4015044A (en) * 1975-03-27 1977-03-29 Union Carbide Corporation Process of bonding polyurethane-sealants and caulks
US4115400A (en) 1976-05-27 1978-09-19 Eli Lilly And Company 1-Azoniabicyclo[3.1.0]hexanes
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
US4311833A (en) * 1979-03-06 1982-01-19 Daicel Chemical Industries Ltd. Process for preparing ethylcarboxymethylcellulose
US4331579A (en) * 1979-10-04 1982-05-25 Congoleum Corporation Adhesive to adhere impervious and felt backed vinyl sheet material to damp concrete
US4322426A (en) * 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4466968A (en) 1980-11-24 1984-08-21 Dermall, Ltd. Method for prophylaxis or treatment of emesis and nausea
US4427676A (en) * 1980-12-19 1984-01-24 John Wyeth & Brother Ltd. Thiomorpholine derivatives
US4376144A (en) * 1981-04-08 1983-03-08 Monsanto Company Treated fibers and bonded composites of cellulose fibers in vinyl chloride polymer characterized by an isocyanate bonding agent
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS58141225A (ja) * 1982-02-16 1983-08-22 Takasago Corp 芳香材用樹脂組成物
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
JPS59500418A (ja) 1982-03-16 1984-03-15 ザ ロツクフエラ− ユニバ−シテイ 胃腸能動作用障害を回復する方法
US4457907A (en) 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
US4518433A (en) * 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4462839A (en) 1983-06-16 1984-07-31 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4581456A (en) * 1983-09-21 1986-04-08 Eli Lilly And Company Processes for preparing picenadol precursors and novel intermediates thereof
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4689332A (en) 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4654390A (en) * 1984-08-10 1987-03-31 The Dow Chemical Company Monomeric plasticizers for halogen-containing resins
JPS6229515A (ja) 1985-07-30 1987-02-07 Shinjiro Tsuji 硬カプセル剤のフイルムコ−テイング方法
US4806556A (en) * 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US4730048A (en) * 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4719215A (en) * 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
DE3609073C2 (de) 1986-03-18 1995-08-10 Hans J Prof Dr Rer Nat Schmitt Meßeinrichtung zur nichtinvasiven Feststellung peripherer Abfluß- und Durchflußstörungen in menschlichen Extremitäten
US4673679A (en) 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
GB8711536D0 (en) * 1986-05-27 1987-06-17 Ici Plc Sealant compositions
AU604052B2 (en) 1986-08-28 1990-12-06 Enzacor Properties Limited Animal growth promotant
US5597564A (en) * 1986-08-28 1997-01-28 Enzacor Properties Limited Method of administering a microgranular preparation to the intestinal region of animals
US4888346A (en) 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
FR2609632B1 (fr) 1987-01-21 1991-03-29 Shelly Marc Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
NL8700842A (enExample) 1987-04-10 1988-11-01 Duphar Int Res
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
CA1315689C (en) 1987-09-03 1993-04-06 Leon I. Goldberg Quarternary derivatives of noroxymorphone which relieve nausea and emesis
ES2051742T3 (es) 1987-09-10 1994-07-01 Univ Chicago Derivados cuaternarios de noroxi-morfina que mitigan las nauseas y la emesis.
US5179138A (en) * 1988-01-25 1993-01-12 Chisso Corporation Process for producing a vinyl chloride resin composition for powder molding
US4912114A (en) * 1988-03-18 1990-03-27 Sandoz Ltd. Morphinan derivatives
EP0352361A1 (en) 1988-07-29 1990-01-31 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4857533A (en) 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5102887A (en) * 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US4965269A (en) 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
RU2147875C1 (ru) 1990-05-11 2000-04-27 Пфайзер Инк. Способ и композиция для снижения кровяного давления и лечения застойной сердечной недостаточности у млекопитающего
JPH04230625A (ja) * 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法
DE69231274T2 (de) 1991-02-25 2000-11-30 Trustees Of Boston University, Boston Hyperkinetische bewegungsstörung modulierender opiatrezeptor-antagonist
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5250542A (en) 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
CA2064373C (en) 1991-03-29 2005-08-23 Buddy Eugene Cantrell Piperidine derivatives
US5270328A (en) 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
CA2110899C (en) * 1991-06-21 2006-08-08 Jacob G. Michael Orally administrable therapeutic proteins and method of making
US5458953A (en) * 1991-09-12 1995-10-17 Mannington Mills, Inc. Resilient floor covering and method of making same
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5614219A (en) * 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
NZ249346A (en) 1992-02-24 1995-10-26 Merrell Dow Pharma 2,6-methano-2h-quinolizine ester derivatives and medicaments thereof
US5401708A (en) * 1992-05-19 1995-03-28 Kanzaki Paper Mfg. Co., Ltd. Heat-sensitive recording material
US5472943A (en) 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
EP1238986B1 (en) 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
ES2095001T5 (es) * 1992-12-22 2001-03-16 Univ Cincinnati Una composicion terapeutica administrable oralmente y su metodo de obtencion.
DE4303214A1 (de) 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5391372A (en) * 1993-06-28 1995-02-21 Campbell; Elizabeth Methods of treating colic and founder in horses
GB2281205A (en) 1993-08-24 1995-03-01 Euro Celtique Sa Oral opioid analgesic
WO1995009168A1 (en) 1993-09-30 1995-04-06 Tokyo Tanabe Company Limited Indoline compound and 5-ht3 receptor antagonist containing the same as active ingredient
US5489618A (en) * 1993-11-29 1996-02-06 Osi Specialties, Inc. Process for preparing polyurethane foam
US5434171A (en) 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
DE69503126T2 (de) 1994-05-05 1998-11-12 Beckman Instruments Inc Repetitive oligonukleotide matrix
IT1269826B (it) 1994-05-24 1997-04-15 Paolo Minoia Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5614222A (en) * 1994-10-25 1997-03-25 Kaplan; Milton R. Stable aqueous drug suspensions and methods for preparation thereof
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US5519072A (en) * 1995-02-15 1996-05-21 National Starch And Chemical Investment Holding Corporation Aqueous adhesive compositions for use in binding books
US6096763A (en) 1995-02-23 2000-08-01 Merck & Co., Inc. α1a adrenergic receptor antagonists
US6025154A (en) * 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US5900464A (en) * 1995-07-25 1999-05-04 Fmc Corporation Processes for making methacrylate and acrylate polymers
US5750278A (en) * 1995-08-10 1998-05-12 Westinghouse Electric Corporation Self-cooling mono-container fuel cell generators and power plants using an array of such generators
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5804595A (en) 1995-12-05 1998-09-08 Regents Of The University Of Minnesota Kappa opioid receptor agonists
PT914097E (pt) 1996-03-12 2002-06-28 Alza Corp Composicao e forma de dosagem compreendendo antagonista de opioide
US6136780A (en) * 1996-03-29 2000-10-24 The Penn State Research Foundation Control of cancer growth through the interaction of [Met5 ]-enkephalin and the zeta (ζ) receptor
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US5856369A (en) * 1996-07-30 1999-01-05 Osi Specialties, Inc. Polyethers and polysiloxane copolymers manufactured with double metal cyanide catalysts
JP3648864B2 (ja) 1996-08-28 2005-05-18 三菱自動車工業株式会社 希薄燃焼内燃機関
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US20010036469A1 (en) 1997-01-13 2001-11-01 Gooberman Lance L. Opiate antagonist implant and process for preparation therefor
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6858260B2 (en) * 1997-05-21 2005-02-22 Denovus Llc Curable sealant composition
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
US6525038B1 (en) * 1997-06-24 2003-02-25 Werner Kreutz Synergistic compositions for the selective control of tumor tissue
US6353004B1 (en) * 1997-07-14 2002-03-05 Adolor Coporation Peripherally acting anti-pruritic opiates
US6096764A (en) 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6777534B1 (en) 1997-12-09 2004-08-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
ES2412409T3 (es) * 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
EP0930334A1 (en) 1998-01-16 1999-07-21 Quest International B.V. Polysaccharide conjugate capable of binding cellulose
CA2326761C (en) * 1998-04-03 2008-02-19 Ajinomoto Co., Inc. Antitumor agent
US6359111B1 (en) * 1998-05-28 2002-03-19 Neorx Corporation Opioid receptor targeting
HN1999000149A (es) * 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
EP1138704B1 (en) * 1998-09-14 2005-04-27 Kaneka Corporation Curable compositions
US20010010919A1 (en) 1998-10-13 2001-08-02 David K. Grandy Opioid antagonists and methods of their use
US6034168A (en) * 1998-10-23 2000-03-07 Ato Findley, Inc. Hot melt adhesive having controllable water solubility
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
JP4049477B2 (ja) 1999-03-23 2008-02-20 大鵬薬品工業株式会社 副作用軽減剤
US6231849B1 (en) * 1999-03-25 2001-05-15 George A. Schiller Simulated seminal fluid
US7129265B2 (en) 1999-04-23 2006-10-31 Mason R Preston Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
US6171620B1 (en) 1999-04-27 2001-01-09 Health Research, Inc. Method of enhancing the efficacy of anti-tumor agents
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6765010B2 (en) 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US20020068712A1 (en) 1999-07-23 2002-06-06 Troy Stevens Use of decreasing levels of functional transient receptor potential gene product
US20030105121A1 (en) 1999-07-27 2003-06-05 Bernard Bihari Method of preventing lipodystrophy syndrome or reversing a pre-existing syndrome in HIV-infected patients being treated with antiretroviral agents
CA2380524A1 (en) 1999-08-25 2001-03-01 Barrett R. Cooper Compositions and methods for treating opiate intolerance
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
EP1225897B1 (en) 1999-11-01 2004-09-08 RHODES, John Composition for treatment of constipation and irritable bowel syndrome
ES2251168T3 (es) * 1999-11-04 2006-04-16 Institut Gustave Roussy Agente antiviral en combinacion con radioterapia para el tratamiento del cancer.
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
WO2001041705A2 (en) 1999-11-29 2001-06-14 Adolor Corporation Novel methods for the treatment and prevention of dizziness and pruritus
MXPA02005336A (es) 1999-11-29 2003-01-28 Adolor Corp Metodos novedosos para el tratamiento y prevencion del ileo.
US6384044B1 (en) 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
NZ518562A (en) 1999-11-29 2005-04-29 Adolor Corp Novel methods and compositions involving opioids and antagonists thereof
US7208464B2 (en) * 2000-06-02 2007-04-24 The Procter & Gamble Company Fragrance compositions
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
US20010046968A1 (en) 2000-03-23 2001-11-29 Zagon Ian S. Opioid growth factor modulates angiogenesis
DE10015981A1 (de) * 2000-03-30 2001-10-11 Beiersdorf Ag Herstellung von Acrylat-Schmelzhaftklebern aus wässrigen dispersen Systemen
US6967075B2 (en) 2000-04-07 2005-11-22 Schering Corporation HCV replicase complexes
AU5714601A (en) 2000-04-19 2001-10-30 Univ Johns Hopkins Methods for prevention and treatment of gastrointestinal disorders
AU5945801A (en) 2000-05-05 2001-11-20 Pain Therapeutics Inc Opoid antagonist compositions and dosage forms
WO2001090248A2 (en) * 2000-05-19 2001-11-29 Henkel Loctite Corporation Impregnation sealants utilizing hydrosilation chemistry
US7534772B2 (en) * 2000-06-22 2009-05-19 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
EP1175905A1 (en) 2000-07-24 2002-01-30 Societe Des Produits Nestle S.A. Nutritional Composition
RU2241462C2 (ru) 2000-07-28 2004-12-10 Ф. Хоффманн-Ля Рош Аг Новая фармацевтическая композиция
US6706399B1 (en) * 2000-08-29 2004-03-16 Eastman Chemical Company Non-blocking polymeric articles
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
WO2002060870A2 (en) 2000-11-17 2002-08-08 Adolor Corporation Delta agonist analgesics
ES2445748T3 (es) 2000-12-04 2014-03-05 Primagen B.V. Ensayos basados en ácidos nucleicos de orgánulos celulares endosimbiontes
US7259233B2 (en) 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20020172712A1 (en) 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
HUP0400314A3 (en) 2001-03-23 2006-02-28 Shire Biochem Inc Laval Pharmaceutical combinations for the treatment of cancer
AU2002252444A1 (en) * 2001-03-23 2002-10-08 Board Of Regents, The University Of Texas System Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors
US6846929B2 (en) * 2001-04-02 2005-01-25 Ciba Specialty Chemicals Corporation Benzotriazole/hals molecular combinations and compositions stabilized therewith
US20040242523A1 (en) 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
AU2002259045B2 (en) 2001-04-26 2008-05-22 Psivida Us Inc. Sustained release drug delivery system containing codrugs
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
EP1404323B1 (en) 2001-06-05 2009-10-28 The University of Chicago Use of methylnaltrexone to treat immune suppression
US6675560B2 (en) * 2001-06-29 2004-01-13 Eastman Chemical Company PVC food wrap formed from dioctyl terphthalate plasticizer, method of forming same and method of wrapping food therewith
AU2002328338C1 (en) * 2001-07-16 2009-01-08 Ono Pharmaceutical Co., Ltd 2 pyrrolidone derivatives as prostanoid agonists
US8012517B2 (en) * 2001-08-31 2011-09-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels with extracts of noni juice Morinda citrifolia
MXPA04002006A (es) 2001-08-31 2004-06-07 Sucampo Ag Analogos de prostagladina como abridor del canal de cloruro.
US7012148B2 (en) * 2001-09-25 2006-03-14 Trustees Of Dartmouth College Compositions and methods for thionation during chemical synthesis reactions
PT2939696E (pt) 2001-10-18 2016-06-17 Nektar Therapeutics Conjugados poliméricos de antagonistas de opióides
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
WO2003037365A1 (en) * 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
US6855765B2 (en) * 2001-12-12 2005-02-15 National University Of Singapore Heat and hot water resistant polyurethane sealant
US7371767B2 (en) * 2001-12-21 2008-05-13 Merck & Co., Inc. Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
US20040259898A1 (en) 2002-02-04 2004-12-23 Jonathan Moss Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
US20050011468A1 (en) * 2002-02-04 2005-01-20 Jonathan Moss Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
US7074825B2 (en) 2002-03-07 2006-07-11 Huanbiao Mo Composition and method for treating cancer
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
US7355081B2 (en) 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
WO2003099833A2 (en) * 2002-05-17 2003-12-04 Board Of Regents, The University Of Texas System Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
US7012100B1 (en) * 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
EP1803821B1 (en) 2002-06-05 2012-02-29 Cedars-Sinai Medical Center Methods for managing kinase inhibitor therapy
EP1522542A1 (en) 2002-07-11 2005-04-13 Toray Industries, Inc. Therapeutic or preventive agent for nausea/vomiting
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
US7691374B2 (en) * 2002-10-23 2010-04-06 Health Research, Inc. Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody
WO2004043964A2 (en) 2002-11-08 2004-05-27 Mallinckrodt Inc. Process for the preparation of quaternary n-alkyl morphinan alkaloid salts
WO2004054569A1 (en) * 2002-12-16 2004-07-01 Council Of Scientific And Industrial Research Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings
US20060281682A1 (en) 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
EP1596844A2 (en) 2003-01-30 2005-11-23 Dynogen Pharmaceuticals Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
MXPA05009367A (es) * 2003-03-07 2005-11-04 Lilly Co Eli Antagonistas del receptor opioide.
BRPI0409133B8 (pt) 2003-04-08 2021-05-25 Progenics Pharm Inc preparações farmacêuticas estavéis compreendendo metilnaltrexona
EP1617846A1 (en) 2003-04-08 2006-01-25 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
RU2005134364A (ru) 2003-04-08 2006-06-10 Проджиникс Фармасьютикалз, Инк. (Us) Комбинированное лечение запора
ES2639579T3 (es) 2003-04-29 2017-10-27 Orexigen Therapeutics, Inc. Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión
US6992193B2 (en) 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use
DK1644021T3 (da) * 2003-06-13 2012-10-29 Ironwood Pharmaceuticals Inc Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
AU2003903387A0 (en) 2003-07-02 2003-07-17 Sirtex Medical Limited Combination therapy for treatment of neoplasia
US7066888B2 (en) 2003-10-29 2006-06-27 Allez Physionix Ltd Method and apparatus for determining an ultrasound fluid flow centerline
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005087208A2 (en) * 2004-03-10 2005-09-22 Trustees Of Tufts College Synergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
US6946556B1 (en) 2004-05-21 2005-09-20 Acura Pharmaceuticals, Inc. Preparation of opioid analgesics by a one-pot process
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US7388008B2 (en) * 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
EP1799713B1 (en) 2004-09-23 2014-11-05 VasGene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1845989A1 (en) 2005-01-20 2007-10-24 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
BRPI0608818A2 (pt) 2005-03-07 2010-01-26 Univ Chicago uso de antagonista opióides para atenuação de proliferação e migração de células endoteliais
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20080194611A1 (en) 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
CA2609985A1 (en) * 2005-06-03 2007-05-10 The University Of Chicago Modulation of cell barrier dysfunction
EP1906838A4 (en) 2005-06-03 2008-10-08 Univ Chicago MODULATION OF MICROBIAL PATHOGENIC HOST CELL INTERACTIONS
EP1906951A4 (en) * 2005-07-01 2009-05-27 Dynogen Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL HYPOMOTILITY AND RELEVANT DISEASES
US7343834B2 (en) * 2005-07-15 2008-03-18 Howlett Marc K Beverage holder
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US20090253634A1 (en) 2005-08-19 2009-10-08 Microbia, Inc. Methods and Compositions for the Treatment of Gastrointestinal Disorders
AU2006287070A1 (en) * 2005-08-30 2007-03-08 Queen's University At Kingston Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptoi agonists using an ultralow dose of an alpha-2 receptor antagonist
WO2007055806A1 (en) 2005-10-31 2007-05-18 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r,4r)-δ8-tetrahydrocannabinol-11-oic acids
US20070259939A1 (en) 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
EP2057243B1 (en) * 2006-08-30 2013-01-23 Eastman Chemical Company Sealant compositions having a novel plasticizer
KR101374888B1 (ko) * 2007-07-20 2014-03-13 한양대학교 산학협력단 접착조성물, 접착조성물의 제조방법, 표시장치 및표시장치의 제조방법
JP5905198B2 (ja) 2007-10-01 2016-04-20 ザ ユニヴァーシティー オヴ シカゴ 薬剤誘発性吐き気のオピオイド拮抗薬による治療
WO2009076195A1 (en) 2007-12-05 2009-06-18 The University Of Chicago Treatment of drug-induced nausea with opioid antagonists
EP2252150B1 (en) 2008-02-14 2018-04-11 Alkermes, Inc. Selective opioid compounds

Similar Documents

Publication Publication Date Title
JP2009533482A5 (enExample)
JP2017504611A5 (enExample)
JP2021169479A5 (enExample)
JP2011006480A5 (enExample)
JP7668777B2 (ja) 癌治療
JP2008531749A5 (enExample)
JP2015512398A5 (enExample)
JP2016526540A5 (enExample)
JP2014512356A5 (enExample)
JP2014518266A5 (enExample)
JP2016041733A5 (enExample)
JP2019501204A5 (enExample)
JP2015508103A5 (enExample)
JP2015534577A5 (enExample)
JP2012153722A5 (enExample)
CN105120663B (zh) 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物
JP2010539082A5 (enExample)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
JP2013523843A5 (enExample)
JP2006502132A5 (enExample)
JP2016523907A5 (enExample)
JP2017514800A5 (enExample)
Awada et al. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
JP2013518036A5 (enExample)
JP2019524713A5 (enExample)